
    
      Since currently there is no standard therapy for untreated advanced-stage low-grade B-cell
      lymphoma, Phase 2/3 study was planned. Comparison(s): An intensified bi-weekly version by
      shortening the intervals of both rituximab and CHOP therapies using G-CSF, compared to the
      tri-weekly R-CHOP regimen.
    
  